Proteintech, a global supplier of antibodies and life science solutions, has introduced Able AI, a new artificial intelligence-powered tool designed to assist researchers in selecting appropriate antibodies for their experiments. The tool is accessible at no cost through the company’s website, ptglab.com.
The selection of suitable antibodies can often be a time-consuming and challenging process for scientists due to the sheer number of available products. Able AI aims to address this problem by offering targeted recommendations based on specific research needs. The platform also provides comprehensive details on each product, including associated scientific literature and experimental protocols.
This development follows the earlier release of Proteintech‘s 3D Epitope Mapping platform. This platform uses AI-driven modeling to visualize antibody binding sites, further enhancing experimental design and reducing reliance on trial-and-error methods.
Dr. Jason Li, CEO of Proteintech, explained that Able AI represents a significant step forward in the company’s commitment to supporting scientific research. He emphasized the tool’s capacity to streamline workflows and allow researchers to concentrate their efforts on innovative discoveries. Dr. Li highlighted the integration of Able AI with the 3D Epitope Mapping platform as a key element of Proteintech‘s ongoing efforts to improve research processes.
Proteintech, established in 2001, is a major producer of antibodies, proteins, nanobodies, and immunoassays. The company boasts a substantial portfolio of self-manufactured antibodies covering a significant portion of the human proteome, alongside a wide array of other life science reagents. Proteintech‘s facilities maintain ISO13485 and ISO9001 accreditations. The company’s products are cited in over 300,000 publications.
Able AI is currently available for immediate and free use. The platform offers scientists a valuable resource for optimizing their antibody selection processes and ultimately accelerating scientific progress. The user-friendly interface and comprehensive information provided by Able AI are expected to significantly improve research efficiency.
Related
